Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure

Biochemical Pharmacology

Volumn 75, Issue 6, 2008, Pages 1322-1330

  Veeraveedu, Punniyakoti T ^a   Watanabe, Kenichi ^a   Ma, Meilei ^a   Palaniyandi, Suresh S ^a,c   Yamaguchi, Ken'ichi ^b   Kodama, Makoto ^b   Aizawa, Yoshifusa ^b  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aquaretics; Chronic heart failure; Hyponatremia; V2 receptor antagonism; Vasopressin

Indexed keywords

ALDOSTERONE; ARGIPRESSIN; CARDIAC MYOSIN; FUROSEMIDE; LOOP DIURETIC AGENT; POTASSIUM; RENIN; SODIUM; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; BENZAZEPINE DERIVATIVE; CREATININE; DIURETIC AGENT; VASOPRESSIN RECEPTOR;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DIURESIS; DRUG DOSE COMPARISON; ELECTROLYTE EXCRETION; HEART FAILURE; HEART VENTRICLE REMODELING; HORMONE BLOOD LEVEL; LEWIS RAT; MALE; MYOCARDITIS; NONHUMAN; PLASMA RENIN ACTIVITY; POTASSIUM EXCRETION; PRIORITY JOURNAL; RAT; SODIUM BLOOD LEVEL; SODIUM EXCRETION; ANIMAL; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DRUG ANTAGONISM; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART RATE; METABOLISM; ORGAN SIZE; OSMOLARITY; PATHOLOGY; PATHOPHYSIOLOGY; URINE;

ALDOSTERONE; ANIMALS; ARGININE VASOPRESSIN; BENZAZEPINES; BLOOD PRESSURE; BODY WEIGHT; CREATININE; DIURETICS; ECHOCARDIOGRAPHY; FUROSEMIDE; HEART FAILURE; HEART RATE; MALE; ORGAN SIZE; OSMOLAR CONCENTRATION; POTASSIUM; RATS; RATS, INBRED LEW; RECEPTORS, VASOPRESSIN; RENIN; SODIUM; VENTRICULAR REMODELING;

EID: 39749187298     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.11.011     Document Type: Article

References (46)

1. Haslet C., Chilvers E.R., Hunter J.A.A., and Boon N.A. Davidson's principles and practice of medicine. 18th ed. (1999), Churchill Livingstone, London
2. Abraham W.T., and Schrier R.W. Body fluid volume regulation in health and disease. Adv Intern Med 39 (1994) 23-47
3. Costello-Boerrigter L.C., Smith W.B., Boerrigter G., Ouyang J., Zimmer C.A., Orlandi C., et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 290 (2006) F273-F278
4. Chen H.H., Redfield M.M., Nordstrom L.J., Cataliotti A., and Burnett Jr. J.C. Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. Am J Physiol Renal Physiol 284 (2003) F1115-F1119
5. Gottlieb S.S., Brater D.C., Thomas I., Havranek E., Bourge R., Goldman S., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
6. Vallon V. Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol Sci 18 (2003) 169-174
7. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., and Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35 (2000) 681-689
8. Cooper H.A., Dries D.L., Davis C.E., Shen Y.L., and Domanski M.J. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100 (1999) 1311-1315
9. Domanski M., Norman J., Pitt B., Haigney M., Hanlon S., and Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 42 (2003) 705-708
10. Lee W.H., and Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73 (1986) 257-267
11. Lee C.R., Watkins M.L., Patterson J.H., Gattis W., O'connor C.M., Gheorghiade M., et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 146 (2003) 9-18
12. Burrell L.M., Phillips P.A., Risvanis J., Aldred K.L., Hutchins A.M., and Johnston C.I. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism. Hypertension 26 (1995) 828-834
13. Burrell L.M., Phillips P.A., Stephenson J.M., Risvanis J., Rolls K.A., and Johnston C.I. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 23 (1994) 737-743
14. Naitoh M., Suzuki H., Murakami M., Matsumoto A., Arakawa K., Ichihara A., et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 267 (1994) H2245-H2254
15. 2 antagonist tolvaptan in rats with heart failure. Biochem Pharmacol 74 (2007) 1466-1475
16. Yamamura Y., Nakamura S., Itoh S., Hirano T., Onogawa T., Yamashita T., et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287 (1998) 860-867
17. Gheorghiade M., Niazi I., Ouyang J., Czerwiec F., Kambayashi J., Zampino M., et al. Tolvaptan investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 107 (2003) 2690-2696
18. Udelson J.E., McGrew F.A., Flores E., Ibrahim H., Katz S., Koshkarian G., et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49 (2007) 2151-2159
19. Konstam M.A., Gheorghiade M., Burnett J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. J Am Med Assoc 297 (2007) 1319-1331
20. Gheorghiade M., Konstam M.A., Burnett Jr. J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. J Am Med Assoc 297 (2007) 1332-1343
21. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292 (2000) 288-294
22. Watanabe K., Ohta Y., Nakazawa M., Higuchi H., Hasegawa G., Naito M., et al. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 130 (2000) 1489-1495
23. Kodama M., Matsumoto Y., Fujiwara M., Masani F., Izumi T., and Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 57 (1990) 250-262
24. 2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 146 (2005) 3037-3043
25. Yamaguchi K., Koike M., and Hama H. Plasma vasopressin response to peripheral administration of angiotensin in conscious rats. Am J Physiol 248 (1985) R249-R256
26. Shoker A.S. Application of the clearance concept to hyponatremic and hypernatremic disorders: a phenomenological analysis. Clin Chem 40 (1994) 1220-1227
27. Mallie J.P., Bichet D.G., and Halperin M.L. Effective water clearance and tonicity balance: the excretion of water revisited. Clin Invest Med 20 (1997) 16-24
28. Kinter L.B., Dytko G., Ashton D., McDonald J., Huffman W., and Stassen F. Discovery and therapeutic utility of vasopressin antagonists in rats. J Cardiovasc Pharmacol 8 Suppl 7 (1986) S36-S43
29. Morel F. Sites of hormone action in the mammalian nephron. Am J Physiol 240 (1981) F159-F164
30. Francis G.S., Siegel R.M., Goldsmith S.R., Olivari M.T., Levine T.B., and Cohn J.N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 103 (1985) 1-6
31. Anand I.S., Kalra G.S., Harris P., Poole-Wilson P.A., Panzali A., De Giuli F., et al. Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience 2 (1991) 273-278
32. Lorenz J.N., Weihprecht H., Schnermann J., Skott O., and Briggs J.P. Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport. Am J Physiol 260 (1991) F486-F493
33. Williamson H.E., Bourland W.A., Marchand G.R., Farley D.B., and Van Orden D.E. Furosemide induced release of prostaglandin E to increase renal blood flow. Proc Soc Exp Biol Med 150 (1975) 104-106
34. Abe K., Yasujima M., Chiba S., Irokawa N., Ito T., Yoshinaga K., et al. Effect of furosemide on urinary excretion of prostaglandin E in normal volunteers and patients with essential hypertension. Prostaglandins 14 (1977) 513-521
35. Whorton A.R., Lazar J.D., Smigel M.D., and Oates J.A. Prostaglandin-mediated renin release from renal cortical slices. Adv Prostagl Thromb Res 7 (1980) 1123-1129
36. Beierwaltes W.H., Schryver S., Sanders E., Strand J., and Romero J.C. Renin release selectively stimulated by prostaglandin I2 in isolated rat glomeruli. Am J Physiol 243 (1982) F276-F283
37. Hayashi Y., Hisa H., and Satoh S. Role of prostaglandin in norepinephrine and renin release in canine kidney. Am J Physiol 253 (1987) F929-F934
38. Bailie M.D., Crosslan K., and Hook J.B. Natriuretic effect of furosemide after inhibition of prostaglandin synthetase. J Pharmacol Exp Ther 199 (1976) 469-476
39. Pfeffer M.A., Braunwald E., Moye L.A., Basta L., Brown Jr. E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992) 669-677
40. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
41. Romano G., Favret G., and Bartoli E. Micropuncture study of the effect of furosemide on proximal and distal tubules of the rat nephron. Ren Physiol Biochem 18 (1995) 209-218
42. Tenstad O., and Williamson H.E. Effect of furosemide on local and zonal glomerular filtration rate in the rat kidney. Acta Physiol Scand 155 (1995) 99-107
43. Thibonnier M. Vasopressin receptor antagonists in heart failure. Curr Opin Pharmacol 3 (2003) 683-687
44. Lauson H.D. Metabolism of antidiuretic hormones. Am J Med 42 (1967) 713-744
45. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
46. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321